-
Wunderlich Securities Reiterates Buy and PT of $24 on Abiomed
Wednesday, August 3, 2011 - 8:29am | 47Wunderlich Securities reiterated its Buy rating on Abiomed (NASDAQ: ABMD). At the same time, the rating agency left its price target on the company's stock unchanged at $24. On Tuesday, ABMD lost 4.32% of its value to finish the day at $15.16.
-
St. Jude Medical Board of Directors Authorizes Share Repurchase of up to $500M
Wednesday, August 3, 2011 - 8:18am | 109St. Jude Medical, Inc. (NYSE: STJ) announced today that its Board of Directors has authorized a share repurchase of up to $500 million of its outstanding common stock. The repurchases will occur at such times and at such prices as the management of the Company determines and may be effected through...
-
BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX Molecular Testing System
Wednesday, August 3, 2011 - 8:08am | 100BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Lab21 announced today a collaboration to develop a state-of-the-art molecular diagnostic assay to detect the life-threatening Aspergillus fungus using the new fully automated BD MAX™...
-
Jefferies Reports 2Q Sales On Insulet
Wednesday, August 3, 2011 - 8:08am | 65According to Jefferies, Insulet (NASDAQ: PODD) reported 2Q sales of $32.2mn, largely in-line with expectations. Jefferies said that full year guidance was narrowed to $152-158mn from $150-160mn. “Op expenses took a step up on the Neighborhood integration, but the company remains on track to reach...
-
J.P. Morgan Raises PT To $17 On QDEL
Wednesday, August 3, 2011 - 7:52am | 146J.P. Morgan, in light of the company's mixed quarter, has slightly raised its price target on Quidel (NASDAQ: QDEL) from $16 to $17 but is maintaining its Neutral rating on the stock. In the report, J.P. Morgan writes, “2Q11 revenues came in slightly below consensus, although above our estimates,...
-
Morgan Keegan Maintains Market Perform on AtriCure
Wednesday, August 3, 2011 - 7:45am | 94Morgan Keegan is out with its report today on AtriCure (NASDAQ: ATRC), maintaining Market Perform. In its report, Morgan Keegan writes, "AtriCure reported second quarter results beating our top line expectations because of momentum from International Sales Force expansion, new product...
-
JP Morgan Raises PT on Quidel To $17
Wednesday, August 3, 2011 - 6:50am | 26JP Morgan has raised the price target on Quidel (NASDAQ: QDEL) from $16 to $17 and maintains its Neutral rating.
-
Jefferies Raises PT On Insulet Corporation To $25
Wednesday, August 3, 2011 - 6:20am | 26Jefferies & Company has raised the price target on Insulet (NASDAQ: PODD) from $24 to $25 and maintains its Buy rating.
-
Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows
Wednesday, August 3, 2011 - 1:05am | 5002Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...
-
Cantel Medical Acquires Byrne Medical for $100M
Tuesday, August 2, 2011 - 10:31am | 249Cantel Medical (NYSE: CMN), through its Minntech subsidiary, has acquired the business and substantially all of the assets of Byrne Medical, Inc. Byrne Medical, privately-owned and based outside Houston, TX, designs, manufactures and sells an innovative array of disposable infection control...
-
Options Brief: ResMed
Tuesday, August 2, 2011 - 10:16am | 85Shares of ResMed (NYSE: RMD) are lower on the session by 0.96%, trading at $29.89. Overall call volume is now running at 9.97x the daily average, with 50% of all calls traded being purchases on the offer. 1,935 contracts have traded on the session so far. ResMed Inc., is a holding company for...
-
J.P. Morgan Decreases EPS Estimates Of Volcano Corporation
Tuesday, August 2, 2011 - 9:31am | 54According to J.P. Morgan, Volcano Corporation (NASDAQ: VOLC), EPS estimates have been decreased. J.P. Morgan decreased EPS estimates for FY12 from $0.46 to $0.41 and from $0.76 to $0.73 for FY13. PT has been increased from $33 to $38 and rating is set to Overweight. Volcano Corporation closed...
-
Earnings Roundup
Tuesday, August 2, 2011 - 9:30am | 1919Archer Daniels Midland Co (NYSE: ADM) reported a decline in its fiscal fourth-quarter profit. Archer Daniels Midland reported its quarterly profit at $381 million, or $0.58 per share, down from $446 million, or $0.69 per share, in the year-earlier period. Analysts were expecting earnings of $0.85...
-
Cantel Medical Acquires Byrne Medical; Cantel Will Pay $90M Cash, 401.1k Shares Valued at $10M
Tuesday, August 2, 2011 - 9:04am | 67Cantel Medical Corp (NYSE: CMN), through its Minntech subsidiary, has acquired the business and substantially all of the assets of Byrne Medical, Inc. Byrne Medical, privately-owned and based outside Houston, TX, designs, manufactures and sells an innovative array of disposable infection control...
-
J.P. Morgan Decreases PT Of HOLX From $24 To $20
Tuesday, August 2, 2011 - 9:04am | 57According to J.P. Morgan, Hologic (NASDAQ: HOLX), PT has been decreased from $24 to $20. J.P. Morgan also announced a decrease in EPS estimates in FY11 from $1.25 to $1.24 and from $1.38 to $1.34 in FY12. FY13 EPS estimates are set at $1.42 and rating is set to Overweight. HOLX closed yesterday...